Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

The phenotypic and genetic assessment of antithrombin deficiency.

Cooper PC, Coath F, Daly ME, Makris M.

Int J Lab Hematol. 2011 Jun;33(3):227-37. doi: 10.1111/j.1751-553X.2011.01307.x. Epub 2011 Mar 15. Review.

PMID:
21401902
2.

Great discrepancy in antithrombin activity measured using five commercially available functional assays.

Javela K, Engelbarth S, Hiltunen L, Mustonen P, Puurunen M.

Thromb Res. 2013 Jul;132(1):132-7. doi: 10.1016/j.thromres.2013.05.012. Epub 2013 Jun 12.

PMID:
23768451
3.

Antithrombin deficiency in three Japanese families: one novel and two reported point mutations in the antithrombin gene.

Maruyama K, Morishita E, Karato M, Kadono T, Sekiya A, Goto Y, Sato T, Nomoto H, Omi W, Tsuzura S, Imai H, Asakura H, Ohtake S, Nakao S.

Thromb Res. 2013 Aug;132(2):e118-23. doi: 10.1016/j.thromres.2013.06.001. Epub 2013 Jun 25.

PMID:
23809926
4.

Development of a novel, rapid assay for detection of heparin-binding defect antithrombin deficiencies: the heparin-antithrombin binding (HAB) ratio.

Moore GW, de Jager N, Cutler JA.

Thromb Res. 2015 Jan;135(1):161-6. doi: 10.1016/j.thromres.2014.10.023. Epub 2014 Nov 4.

PMID:
25466846
5.

Antithrombin heparin binding site deficiency: A challenging diagnosis of a not so benign thrombophilia.

Orlando C, Heylen O, Lissens W, Jochmans K.

Thromb Res. 2015 Jun;135(6):1179-85. doi: 10.1016/j.thromres.2015.03.013. Epub 2015 Mar 14.

PMID:
25837307
6.

Antithrombin.

Hepner M, Karlaftis V.

Methods Mol Biol. 2013;992:355-64. doi: 10.1007/978-1-62703-339-8_28.

PMID:
23546728
7.

Laboratory diagnosis of hereditary thrombophilia.

Michiels JJ, Hamulyák K.

Semin Thromb Hemost. 1998;24(4):309-20. Review.

PMID:
9763348
8.

Role of the C-sheet in the maturation of N-glycans on antithrombin: functional relevance of pleiotropic mutations.

Aguila S, Navarro-Fernández J, Bohdan N, Gutiérrez-Gallego R, de la Morena-Barrio ME, Vicente V, Corral J, Martínez-Martínez I.

J Thromb Haemost. 2014 Jul;12(7):1131-40. doi: 10.1111/jth.12606. Epub 2014 Jun 19.

9.

Antithrombin Nagasaki (Ser 116 to Pro): a rare antithrombin variant with abnormal heparin binding presenting during pregnancy.

O'Ddonnell JS, Hinkson L, McCarthy A, Manning R, Khan A, Laffan MA.

Blood Coagul Fibrinolysis. 2006 Apr;17(3):217-20.

PMID:
16575261
10.

An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.

Demers C, Henderson P, Blajchman MA, Wells MJ, Mitchell L, Johnston M, Ofosu FA, Fernandez-Rachubinski F, Andrew M, Hirsh J, et al.

Thromb Haemost. 1993 Mar 1;69(3):231-5.

PMID:
8470046
11.

Inherited antithrombin deficiency: a review.

Patnaik MM, Moll S.

Haemophilia. 2008 Nov;14(6):1229-39. doi: 10.1111/j.1365-2516.2008.01830.x. Review.

PMID:
19141163
12.

Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis.

Lane DA, Lowe GD, Flynn A, Thompson E, Ireland H, Erdjument H.

Br J Haematol. 1987 Aug;66(4):523-7.

PMID:
3663509
13.

Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk.

Rossi E, Chiusolo P, Za T, Marietti S, Ciminello A, Leone G, De Stefano V.

Thromb Haemost. 2007 Sep;98(3):695-7. No abstract available. Erratum in: Thromb Haemost. 2007 Oct;98(4):915.

PMID:
17849067
14.

The superiority of anti-FXa assay over anti-FIIa assay in detecting heparin-binding site antithrombin deficiency.

Kovács B, Bereczky Z, Oláh Z, Gindele R, Kerényi A, Selmeczi A, Boda Z, Muszbek L.

Am J Clin Pathol. 2013 Nov;140(5):675-9. doi: 10.1309/AJCPVY4Z9XZMFOTH.

PMID:
24124146
15.

Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").

Sambrano JE, Jacobson LJ, Reeve EB, Manco-Johnson MJ, Hathaway WE.

J Clin Invest. 1986 Mar;77(3):887-93.

16.

Assessment of interference by heparin cofactor II in the DuPont aca antithrombin-III assay.

Hortin GL, Tollefsen DM, Santoro SA.

Am J Clin Pathol. 1988 Apr;89(4):515-7.

PMID:
3354504
17.

Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.

Martinelli I, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, Paciaroni K, Leone G, Faioni EM.

Blood. 1998 Oct 1;92(7):2353-8.

18.

Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.

Okajima K, Ueyama H, Hashimoto Y, Sasaki Y, Matsumoto K, Okabe H, Inoue M, Araki S, Takatsuki K.

Thromb Haemost. 1989 Feb 28;61(1):20-4.

PMID:
2749590
19.
20.

Enhancement of heparin cofactor II anticoagulant activity.

Bauman SJ, Church FC.

J Biol Chem. 1999 Dec 3;274(49):34556-65.

Supplemental Content

Support Center